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We retrospectively investigated the efficacy and feasibility of individualised chemotherapy based on in vitro drug sensitivity testing
(DST) for patients with glioblastoma multiforme. A total of 40 consecutive patients with glioblastoma multiforme (GM) were enrolled
into this study between January 1995 and December 2000. The flow cytometric (FCM) detection of apoptosis was used to
determine the in vitro sensitivity of tumour cells obtained at surgery to 30 different kinds of anticancer agents. From the results of FCM
assay, an in vitro best regimen was prospectively selected. All the patients concurrently received the individualised chemotherapy with
the in vitro best regimen and 60Gy of conventional radiation therapy. Of the 31 assessable patients, eight patients (26%) achieved
partial response, and 20 patients (65%) had stable disease. The median survival time was 20.5 months. The individualised
chemotherapy based on in vitro DST was associated with favourable survival time for the patients with GM compared with the
reported results of conventional therapy regimens. The present result suggests that the currently available anticancer agents could be
effective against GM when used in individualised chemotherapy.
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Glioblastoma multiforme (GM) is one of the most refractory
cancers to chemotherapy. The best treatment currently available
consists of cytoreductive surgery, followed by 60Gy of radiation
therapy and chemotherapy using nitrosoureas that can penetrate
the blood–brain barrier (BBB) (Shapiro, 1999). This conventional
treatment regimen results in approximately 1 year of median
survival for GM and 2 years for anaplastic astrocytoma (AA) in
consecutive, nonselected patients populations (Takakura et al,
1986; Levin et al, 1990; Hildebrand et al, 1994; Iwadate et al, 1995;
Medical Research Council Brain Tumour Working Party, 2001).
Although chemotherapy contributes to modest but significant
improvement in the survival time of AA, no study has demon-
strated that chemotherapy was linked with an improvement in the
survival of GM patients (Levin et al, 1990; Hildebrand et al, 1994).
Present cancer treatment requires the selection of uniform
therapy regimen for patient disease categories on the basis of
clinical trials in large populations of the patients. Genetic
alterations and gene expression patterns, however, are hetero-
geneous even in the same histological type of tumours, which leads
to heterogeneous responses to the cancer therapies (James and
Olson, 1995; Iwadate et al, 1996, 1998, 2000; Rickman et al, 2001).
This heterogeneity in drug sensitivity would partly account for the
relative lack of success with uniform and conventional chemother-
apy regimens obtained by such a clinical trial (Shapiro, 1999). The
chemotherapy with optimised combinations of anticancer agents
according to the heterogeneity in chemosensitivity could improve
the survival of the patients.
Many in vitro drug-sensitivity tests (DSTs) have been examined
for their predictive accuracy (Salmon et al, 1978; Mosmann, 1983;
Rosenblum et al, 1983; Kimmel et al, 1987, Iwadate et al, 2002).
Among the various assay systems, simple and reliable methods
would enable the design of a specific regimen for an individual
patient in routine clinical works, sparing patients with resistant
tumours the toxicity of ineffective treatment. We have shown that
the flow cytometric (FCM) analysis of DNA integrity, which detects
apoptosis quantitatively as a population of sub-G1 peak, is feasible
and sufficiently reliable as a routine clinical DST (Iwadate et al,
1997). The clinical sensitivity was predicted in 86% of all evaluable
patients and clinical resistance in 81%; the overall accuracy of the
FCM assay was 82% for intracerebral gliomas (Iwadate et al, 2002).
There are few prospective trials on chemotherapy regimens
selected by in vitro DST for extracerebral cancers (Alonso, 1984;
Gazdar et al, 1990, Von Hoff et al, 1990, Sekiya et al, 1991; Cortazar
et al, 1997), and no prospective trial for malignant gliomas. To
verify the hypothesis that chemotherapy with optimised combina-
tions of anticancer agents could improve the survival of patients
with GM, we performed a clinical trial of chemotherapy with
agents prospectively selected by the FCM assay for each patient
(‘individualised chemotherapy’).
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lMATERIALS AND METHODS
Eligibility
This was a multi-institutional study conducted at Chiba University
Hospital and Chiba Cancer Center Hospital to test the hypothesis
that optimised combinations of anticancer agents prospectively
selected by DST could improve the survival of patients with GM.
The primary end point of the study was the overall survival time of
patients who were treated with anticancer agents selected by DST.
Patients were included in the trial if they had been histologically
confirmed, newly diagnosed supratentorial GM. The pathology
specimens obtained at surgical excision or biopsy were reviewed
by a neuropathologist. Other eligibility criteria included the
following; (1) age of 15 years or older; (2) Karnofsky performance
status (KPS) of 50% or greater at the time of assignment; (3)
adequate organ function defined by WBC X3000mL
 1,
plateletsX100000mL
 1, haemoglobinX10.0gdL
 1, bilirubin less
than 1.5mgdL
 1, AST less than two times the upper limit of
normal, and creatinine less than 2.0mgdL
 1. The patients were
informed of the investigational nature of the study and were
required to provide informed consent.
Pretreatment evaluation included a complete medical history, a
physical examination, and a detailed neurological examination.
Laboratory tests included a complete blood count with a platelet
count and blood chemistry. Computed tomography (CT) with
contrast enhancement and magnetic resonance imaging (MRI)
scan with and without gadolinium was performed preoperatively
and postoperatively before the initiation of radiotherapy and
chemotherapy.
In vitro DST
We used direct in vitro measurement of apoptosis as DST. Two
different methods were employed as described previously; FCM
analysis of DNA integrity, by which apoptosis is represented as the
sub-G1 population (Iwadate et al, 1997, 2002), and morphological
observation of nuclear damages (Sekiya et al, 1991). Surgically
resected tumour cells were immediately minced and suspended in
RPMI 1640 supplemented with 10% fetal calf serum. The micro-cell
aggregate suspension was passed through a sterilised mesh several
times to remove fibrous connective tissue, and centrifuged at
1000r.p.m. for 5min to eliminate fatty tissues and necrotic
portions. An aliquot of the cell suspension was incubated
individually with 30 different kinds of anticancer agents
(Table 1). In vitro drug concentrations were set at 1/10 of the
peak plasma concentration when used in the clinically recom-
mended doses (Alberts and Chen, 1980), and the dose–response
evaluation was performed in selected 12 drugs. To evaluate the
pro-drugs adequately, the in vivo activated forms, 4-hydroperox-
ycyclophosphamide and 4-hydroperoxyifosphamide, were used for
Table 1 Anticancer agents: in vitro concentrations and in vivo administration doses
Drugs Abbreviations In vitro In vivo
Alkylating agents
Cyclophosphamide CPM 0.1mgml
 1,1mgml
 1 750mgm
 2
Ifosphamide IFOS 0.1mgml
 1,1mgml
 1 1.0gm
 2 5d
Melphalan MPL 0.5mgml
 1 NU
Carboquone CQ 0.1mgml
 1 NU
Nimustine ACNU 2mgml
 1,2 0mgml
 1 75mgm
 2
Ranimustine MCNU 2mgml
 1 75mgm
 2
Cisplatin CDDP 0.5mgml
 1,5mgml
 1 20mgm
 2 5d
Carboplatin JM-8 4mgml
 1 400mgm
 2
Topoisomerase inhibitors
Actinomycin D ACD 0.01mgml
 1 NU
Adriamycin ADM 0.3mgml
 1,3mgml
 1 40mgm
 2
Daunomycin DM 0.6mgml
 1 40mgm
 2 2d
Pirarubicin THP 0.3mgml
 1 40mgm
 2
Epirubicin 40-EPI 0.4mgml
 1 40mgm
 2
Aclarubicin ACR 0.3mgml
 1, 0.6mg/ml 40mgm
 2
Mitoxantrone MIT 0.06mgml
 1 12mgm
 2 3d
Etoposide VP-16 3mgml
 1,3 0mgml
 1 60mgm
 2 5d
Camptothecin CPT-11 3mgml
 1 NU
Antimetabolites
Methotrexate MTX 3mgml
 1 40mgm
2 2d
5-Fluorouracil 5-FU 10mgml
 1 800mgd
 1 (p.o.)
Thioinosine 6-MPR 3mgml
 1 2mgkg
 1 (p.o.)
Cytosine arabinoside CA 4mgml
 1,4 0mgml
 1 60mgm
 2 7d
Antibiotics
Mitomycin C MMC 0.2mgml
 1,2mgml
 1 10mgm
 2
Bleomycin BLM 1mgml
 1 10Um
 2
Peplomycin PEP 0.1mgml
 1, 0.5mgml
 1 NU
Chlomomycin A3 TM 0.01mgml
 1 NU
Neocarzinostatin NCS 0.15mgml
 1 NU
Antimicrotubule agents
Vincristine VCR 0.02mgml
 1, 0.1mgml
 1 1mgm
 2
Vinblastine VLB 0.1mgml
 1 5mgm
 2
Vindesine VDS 0.1mgml
 1 3mgm
 2
Paclitaxel TAX 0.6mgml
 1,6mgml
 1 100mgm
 2
NU¼not used in this study.
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lcyclophosphamide and ifosfamide, respectively. Cells were in-
cubated with each agent at 371Ci n5 %C O 2 for 8h, and then
cultured in fresh drug-free RPMI 1640 medium with 10% fetal calf
serum for 72h. Then, the FCM analysis of propidium iodide (PI)-
stained nuclei was performed. The treated cells were mixed with
phosphate buffered-saline pH 7.2/0.1% Triton X-100/0.1mgml
 1
RNase/0.01% sodium azide for 15min, and then with 50mgml
 1
propidium iodide (Sigma, St Louis, MO, USA) for 5min. Isolated
nuclei were analysed with a flow cytometer (FACScan: Becton
Dickinson, Mountain View, CA, USA). As apoptotic nuclei shifted
to the hypodiploid (sub-G1) area, the integrated diploid peak (G0/
G1 peak) reciprocally decreased. The effectiveness of the drugs was
judged by reduction in the G0/G1 peak compared with that of
untreated control cells; more than 20% reduction was judged as
positive. In addition to the FCM assay, drug-induced apoptosis was
confirmed morphologically. The treated cells were fixed with 70%
ethanol and stained with Giemsa on a slide glass. A total of 400
nuclei per slide were observed using the high-power field of a light
microscope. Apoptotic changes noted in the nuclei, such as
chromatin degradation or condensation, were judged as markers
of apoptosis, and counted to compare with nontreated controls.
The Fisher’s exact probability test was used to examine the
statistical difference under the level of 5% between the samples and
the nontreated control. This morphological study showed that the
average percentages of tumour cells in the preparations were
constantly over 95. The DNA integrity assessed by the FCM
analysis was well correlated with the morphological changes in the
nuclei. Drugs were finally determined as effective in vitro when
either of the assays was judged as positive to avoid a false-negative
result.
Treatment protocol
Two or three anticancer agents were prospectively selected for each
patient from the results of the DST. When a number of agents were
effective against the tumour sample in vitro, the agents showing
the highest grade of effectiveness were chosen. In the case where
several agents showed almost the same grade of effectiveness, we
chose agents based on their ability to penetrate the BBB, and
preferred to the combination of drugs with different mechanism of
pharmaceutical action. When no agent was positive in vitro, the
patients were treated only with radiation therapy. These patients
were included in the survival study so as to avoid an exclusion
bias. The doses and schedules of individualised chemotherapy
regimens were determined on the basis of the clinically
recommended doses (Table 1). All regimens were given at least
every 3 months for a year. The schedules of individualised
chemotherapy were modified from previously published regimens
to produce similar haematological toxicity. Conventional radiation
therapy with a megavoltage machine was begun within 2 weeks
after surgical removal in conjunction with the chemotherapy. The
initial treatment volume included the contrast-enhancing lesion
surrounding edema plus a 2-cm margin by the preoperative CT
and MRI scan. This treatment volume received a dose of 40Gy in
2-Gy fractions, and an additional 20Gy in 2-Gy fractions was
delivered to the boost volume, which included the contrast-
enhancing lesion plus a 5-mm margin.
Evaluation methods
This trial was designed to estimate the survival time of GM patients
treated with individualised chemotherapy combined with conven-
tional radiotherapy. Survival duration was calculated from the date
of surgery until the date of last follow-up or death. Survival curves
were generated using the Kaplan–Meier method. To evaluate the
initial tumour response to the individualised chemotherapy, MRI
studies were performed before the patient entered the study, after
induction chemotherapy, and after every cycle of maintenance
chemotherapy. Responses were based primarily on the product of
the largest two tumour diameters seen on the MRI study, and were
evaluated according to the response evaluation criteria in solid
tumours (RECIST) (Therasse et al, 2000). Complete response (CR)
was defined as the disappearance of all measurable enhancing
tumour on imaging studies for more than 4 weeks, and
neurologically stable or improved. Partial response (PR) was
defined as a reduction of 50% or greater in the sum of the products
of the largest perpendicular diameters of contrast enhancement for
all measurable lesions or definitely better for all nonmeasurable
lesions on MRI scans for more than 4 weeks. No new lesions could
arise. Progressive disease (PD) was defined as a 25% or greater
increase in the size of the products of the largest perpendicular
diameters of contrast enhancement for any measurable lesions or
definitely worse for all nonmeasurable lesions or any new tumour
on MRI scans. Stable disease (SD) was defined as all other
situations.
RESULTS
Patient characteristics
Consecutive 40 patients who were referred to the two institutes
between January 1995 and December 2000, were enrolled in this
study. Patient age, sex, surgical intervention, KPS score, and
tumour location are listed in Table 2. Patients had a mean age of 51
years (range, 18–70 years). In all, 45% of the patients with GM
were less than 50 years of age. The mean KPS score was 76 at the
time of diagnosis (range, 50–100). All patients underwent maximal
tumour resection with stereotactic biopsy reserved only for
unresectable tumours. In all, 19 patients (48%) underwent a
subtotal resection of the tumour, and six patients (15%) had a total
resection.
In vitro effective agents against GM
Specimens from the 40 patients with GM were investigated by
means of the FCM analysis of DNA integrity and morphological
changes of apoptosis for their susceptibility to the 30 anticancer
agents that are in clinical use. In this series of newly diagnosed
cases with GM, the successful rate of in vitro assay was 100%. The
Table 2 Patient characteristics
No. of cases 40
Age (years)
Mean 51
Range 18B70
Sex
Male 24
Female 16
KPS score
Mean 76
Range 50B100
Tumour location
Left hemisphere 21 (53%)
Right hemisphere 13 (33%)
Midline 6 (15%)
Extent of surgery
Biopsy 4 (10%)
Partial 11 (28%)
Subtotal 19 (48%)
Total 6 (15%)
KPS¼Karnofsky performance status.
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lresults showed that effective agents were markedly heterogeneous
among the patients. Three specimens were judged as negative for
all the 30 anticancer agents. The patients without in vitro effective
agents were treated with radiotherapy alone, and were excluded
from the initial response evaluation but included in the survival
analysis. In vitro effective rates were calculated for each drug
(Table 3), and were relatively high in aclarubicin (25%), etoposide
(20%), and cisplatin (18%). The present result showed that the
effective rates of nitrosoureas, which are the gold standard for the
chemotherapy against GM, was not so high; effective only in one
case (2.5%) for ACNU and in four cases (10%) for MCNU.
Response to treatment
The best initial response to the treatment is summarised in Table 4.
Nine patients were not assessable: six patients had no residual
tumours after surgery and three patients did not receive
chemotherapy because of the all-negative results in the in vitro
DST. Of the 31 assessable patients, there were no CR and eight PRs
(objective response rate, 26%; 95% confidence interval). In total,
20 patients (65%) achieved SD lasting more than 3 months.
Overall survival
The survival time, measured from the time of the first resection or
biopsy, was analysed based on the Kaplan–Meier product-limit
method (Figure 1). The median survival time was 20.5 months, and
the long-term survival rate over 3 years was approximately 10%.
DISCUSSION
Recent advance in the molecular biological analysis of gliomas has
revealed that histologically-identical tumours possess heteroge-
neous gene alterations and thus exhibit heterogeneous sensitivity
to anticancer agents (James and Olson, 1995; Iwadate et al, 1996,
1998, 2000). In vitro DST would provide a rationale for the
selection of therapy for individual patient on the basis of biological
characteristics of the patient’s tumour (Kimmel et al, 1987).
However, it has not been elucidated whether chemotherapy with
prospectively selected agents can improve the patients’ survival
compared with conventional and uniform therapy regimens. We
demonstrated, in the present study, that the chemotherapy with
agents prospectively selected by DST for each patient (individua-
lised chemotherapy) was associated with favourable survival time
in patients with GM. Indeed, the median survival of 20.5 months in
consecutive and nonselected GM patients compares favourably
with most other reported series. This is the first report to show that
the individualised chemotherapy selected by in vitro DST may
contribute to prolongation of the survival period of GM patients.
The methods to predict the clinical response of individual
patients to chemotherapy are classified roughly into two classes.
One approach is molecular tumour analyses including the gene
expression profiles obtained with DNA microarray technology,
which can in part predict the cellular response to the anticancer
agents from the gene expression profile (Dan et al, 2002). The
other approach is the in vitro DST using cell-culture technique
(Kimmel et al, 1987). The DST frequently used at this time is the
colony-forming assay (CFA) and the 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) assay (Salmon et al, 1978;
Mosmann, 1983; Rosenblum et al, 1983). Although the CFA is
considered to be reliable for predicting the clinical response to
therapies, it is time- and cost-consuming, labour-intensive, and
suffers from a low success rate. It is because few prospective trials
Table 3 In vitro effective rates for each anticancer agent
Drugs No. of effective cases Effective rate (%)
Alkylating agents
Cyclophosphamide 4 10
Ifosphamide 4 10
Melphalan 1 2.5
Carboquone 2 5
Nimustine 1 2.5
Ranimustine 4 10
Cisplatin 9 18
Carboplatin 2 5
Topoisomerase inhibitors
Actinomycin D 0 0
Adriamycin 3 7.5
Daunomycin 6 15
Pirarubicin 5 12.5
Epirubicin 3 7.5
Aclarubicin 10 25
Mitoxantrone 3 7.5
Etoposide 8 20
Camptothecin 1 2.5
Antimetabolites
Methotrexate 2 5
5-Fluorouracil 3 7.5
Thioinosine 2 5
Cytosine arabinoside 5 12.5
Antibiotics
Mitomycin C 4 10
Bleomycin 2 5
Peplomycin 2 5
Chlomomycin A3 1 2.5
Neocarzinostatin 1 2.5
Antimicrotubule agents
Vincristine 6 15
Vinblastine 3 7.5
Vindesine 5 12.5
Paclitaxel 6 15
Table 4 Initial tumour response to the individualised chemotherapy
CR PR SD PD NE n RR
Glioblastoma multiforme 0 8 20 3 9 40 26%
CR¼complete response; PR¼partial response; SD¼stable disease; PD¼progres-
progressive disease; NE¼not evaluable; RR¼response rate.
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Figure 1 Kaplan–Meier overall survival for the patients with GM.
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lfor gliomas have attempted to select prospective therapy on the
basis of in vitro analyses. In this study, we used a direct in vitro
measurement of apoptosis by the FCM analysis of DNA integrity as
a DST. This method has been widely used in basic laboratory
studies to detect apoptosis quantitatively (Nicoletti et al, 1991;
Darzynkiewicz et al, 1992; Iwadate et al, 1997). When used as a
DST, the clinical sensitivity was predicted in 86% and clinical
resistance in 81% for the patients with intracerebral gliomas
(Iwadate et al, 2002). Since the flow cytometer directly measure the
nuclear damage of each tumour cell at the final stage of the assay,
strict single-cell suspension is theoretically unnecessary at the
initial stage. This feature would contribute to the high success rate
and the high predictive accuracy. Although the in vitro DST suffers
from difficulties in duplicating the complex conditions of in vivo
therapy, they would have some advantages over the gene
expression analyses because numerous known and unknown
molecular networks influence the susceptibility of the tumour
cells to anticancer agents.
The initial response rate for GM was 26% in the present series,
and the SD was accomplished in 65% of the patients. These results
suggest that the individualised chemotherapy is not curative, but
effectively induces the tumour to enter a dormant state. Because
the currently available anticancer agents have low tumour-
specificity, a complete cure of solid tumours such as GM cannot
be obtained with chemotherapy. The main advantage of indivi-
dualised chemotherapy using an optimised combination of agents
seems to be that tumour dormancy can be obtained without dose-
escalation. In summary, it is reasonable to conclude from the
present study that chemotherapy even with the currently available
agents provides an opportunity to improve the survival of patients
with GM when applied in a specific regimen prospectively selected
for individual patients using in vitro DST. However, further
observations will be required to determine whether the potential
therapeutic benefit is directly associated with administering the
individualised chemotherapy. The present result warrants the use
of this strategy in a larger controlled randomised study.
REFERENCES
Alberts D, Chen HSG (1980) Tabular Summary of Pharmacokinetic
Parameters Relevant to In Vitro Drug Assay. New York: Alan R Liss
pp 351–359
Alonso K (1984) Human tumor stem cell assay. A prospective clinical trial.
Cancer 54: 2475–2479
Cortazar P, Gazdar AF, Woods E, Russel E, Steinberg SM, Williams J, Ihde
DC, Johnson BE (1997) Survival of patients with limited-stage small cell
lung cancer treated with individualized chemotherapy selected by in
vitro drug sensitivity testing. Clin Cancer Res 3: 741–747
Dan S, Tsunoda T, Kitahara O, Yanagawa R, Zembutsu H, Katagiri T,
Yamazaki K, Nakamura Y, Yamori T (2002) An integrated database of
chemosensitivity to 55 anticancer drugs and gene expression profiles of
39 human cancer cell lines. Cancer Res 62: 1139–1147
Darzynkiewicz Z, Bruno S, Del Bino G, Gorczyca W, Hotz MA, Lassota P,
Traganos F (1992) Features of apoptotic cells measured by flow
cytometry. Cytometry 13: 795–808
Gazdar AF, Steinberg SM, Russell EK, Linnoila RI, Oie HK, Ghosh BC,
Cotelingam JD, Johnson BE, Minna JD, Ihde DC (1990) Correlation of in
vitro drug-sensitivity testing with response to chemotherapy and survival
in extensive-stage small cell lung cancer: a prospective clinical trial.
J Natl Cancer Inst 82: 117–124
Hildebrand J, Sahmoud T, Mignolet F, Brucher JM, Afra D (1994) Adjuvant
therapy with dibromodulcitol and BCNU increases survival of adults
with malignant gliomas. EORTC Brain Tumor Group. Neurology 44:
1479–1483
Iwadate Y, Fujimoto S, Sueyoshi K, Namba H, Tagawa M, Yamaura A
(1997) Prediction of drug cytotoxicity in 9L rat brain tumor by using
flow cytometry with a deoxyribonucleic acid-binding dye. Neurosurgery
40: 782–788
Iwadate Y, Fujimoto S, Tagawa M, Namba H, Sueyoshi K, Hirose M,
Sakiyama S (1996) Association of p53 gene mutation with decreased
chemosensitivity in human malignant gliomas. Int J Cancer 69: 236–240
Iwadate Y, Fujimoto S, Yamaura A (2002) Differential chemosensitivity in
human intra-cerebral gliomas measured by flow cytometric DNA
analysis. Int J Mol Med 10: 187–192
Iwadate Y, Mochizuki S, Fujimoto S, Namba H, Sakiyama S, Tagawa M,
Yamaura A (2000) Alteration of CDKN2/p16 in human astrocytic tumors
is related with increased susceptibility to antimetabolite anticancer
agents. Int J Oncol 17: 501–505
Iwadate Y, Namba H, Sueyoshi K (1995) Intra-arterial ACNU and cisplatin
chemotherapy for the treatment of glioblastoma multiforme. Neurol Med
Chir (Tokyo) 35: 598–603
Iwadate Y, Tagawa M, Fujimoto S, Hirose M, Namba H, Sueyoshi K,
Sakiyama S, Yamaura A (1998) Mutation of the p53 gene in human
astrocytic tumors correlates with increased resistance to DNA-damaging
agents but not to anti-microtubule anti-cancer agents. Br J Cancer 77:
547–551
James CD, Olson JJ (1995) Molecular genetics and molecular biology
advances in brain tumors. Curr Opin Oncol 8: 188–195
Kimmel DW, Shapiro JR, Shapiro WR (1987) In vitro drug sensitivity
testing in human gliomas. J Neurosurg 66: 161–171
Levin VA, Yung WK, Bruner J, Kyritsis A, Leeds N, Gleason MJ, Hess KR,
Meyers CA, Ictech SA, Chang E, Maor MH (1990) Superiority of post-
radiotherapy adjuvant chemotherapy with CCNU, procarbazine and
vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final
report. Int J Radiat Oncol Biol Phys 18: 321–324
Mosmann T (1983) Rapid colorimetric assay for cellular growth and
survival: application to proliferation and cytotoxicity assays. J Immunol
Methods 65: 55–63
Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C (1991) A
rapid and simple method for measuring thymocyte apoptosis by
propidium iodide staining and flow cytometry. J Immunol Methods
139: 271–279
Medical Research Council Brain Tumour Working Party (2001) Rando-
mized trial of procarbazine, lomustine, and vincristine in the adjuvant
treatment of high-grade astrocytoma: a medical research council trial. J
Clin Oncol 19: 509–518
Rickman DS, Bobek MP, Misek DE, Kuick R, Blaivas M, Kurnit DM, Taylor
J, Hanash SM (2001) Distinctive molecular profiles of high-grade and
low-grade gliomas based on oligonucleotide microarray analysis. Cancer
Res 61: 6885–6891
Rosenblum ML, Gerosa MA, Wilson CB, Barger GR, Pertuiset BF, de
Tribolet N, Dougherty DV (1983) Stem cell studies of human malignant
brain tumors. J Neurosurg 58: 170–176
Salmon SE, Hamburger AW, Soehnlen B, Durie BG, Alberts DS, Moon TE
(1978) Quantitation of differential sensitivity of human-tumor stem cells
to anticancer drugs. N Engl J Med 298: 1321–1327
Sekiya S, Iijima N, Oosaki T, Takamizawa H, Tokita H (1991) A newly
developed in vitro chemosensitivity test (nuclear damage assay):
application to ovarian cancer. Gynecol Oncol 40: 138–143
Shapiro WR (1999) Current therapy for brain tumors: back to the future.
Arch Neurol 56: 429–432
Takakura K, Abe H, Tanaka R, Kitamura K, Miwa T, Takeuchi K,
Yamamoto S, Kageyama N, Handa H, Mogami H, Nishimoto A, Uozumi
T, Matsutani M, Nomura K (1986) Effects of ACNU and radiotherapy on
malignant glioma. J Neurosurg 64: 53–57
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein
L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther
SG (2000) New guidelines to evaluate the response to treatment in solid
tumors. J Natl Cancer Inst 92: 205–216
Von Hoff DD, Sandbach JF, Clark GM, Turner JN, Forseth BF, Piccart MJ,
Colombo N, Muggia FM (1990) Selection of cancer chemotherapy
for a patient by an in vitro assay versus a clinician. J Natl Cancer Inst 82:
110–116
Individualised chemotherapy for glioblastoma
Y Iwadate et al
1900
British Journal of Cancer (2003) 89(10), 1896–1900 & 2003 Cancer Research UK
C
l
i
n
i
c
a
l